HNSCC & BIOMARKERS OF SIGNIFICANCE

Head and neck cancer is among the leading causes of cancer-related deaths worldwide, with squamous cell carcinomas accounting for the majority of head and neck cancers.

HNSCC & BIOMARKERS OF SIGNIFICANCE

Head and neck cancer is among the leading causes of cancer-related deaths worldwide, with squamous cell carcinomas accounting for the majority of head and neck cancers.

HNSCC by the numbers

Head and neck cancers are the
6th most common
cancer worldwide
In the US, approximately
67,000 new
head and neck cases are
predicted for 2021
For head and neck cancers
over 90%
are squamous cell carcinomas

Recurrent/metastatic (R/M) HNSCC is a morbid and fatal disease. Among patients with locally advanced disease, the 5-year survival rate is approximately 55%. For metastatic HNSCC, the 5-year overall survival is around 15%-35%. Despite recent advances in treatment, including the addition of immuno-oncology, prognosis remains poor, especially in patients with R/M disease.

Prognosis varies based on numerous factors including location and type of HNSCC as well as biomarkers, disease stage at diagnosis and other risk factors. In general, prognosis is poor with the median survival ranging around 6 to 15 months depending on patient- and disease-related factors. The American Cancer Society predicts about 10,850 deaths in the US from oral cavity or oropharyngeal cancer in 2021 – the most common types of HNSCC. Additionally, patients with metastatic oral cavity or oropharyngeal cancer have a 5-year survival rate of less than 40%.

WHAT may be driving your patient's HNSCC?

Understanding the unique biomarkers and genetic drivers behind your patient’s cancer is critical to gathering prognosis information and helping to determine the optimal treatment path and/or clinical trials for consideration.

Biomarkers associated with HNSCC can include:

Performing routine genetic testing to uncover biomarkers of significance is becoming an important part of HNSCC management.